PT-141

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, with primary activity at MC3R and MC4R subtypes located in the central nervous system. Unlike phosphodiesterase inhibitors that act peripherally on vascular smooth muscle, PT-141 exerts its effects through central nervous system pathways in the hypothalamus.

Melanocortin-4 receptors (MC4R) in the hypothalamus are critical regulators of sexual arousal, appetite, and energy homeostasis. When PT-141 activates MC4R, it initiates a dopaminergic cascade in the medial preoptic area and paraventricular nucleus, stimulating the neural pathways responsible for sexual desire and arousal. This central mechanism means PT-141 addresses the motivational/desire component of sexual function, not merely the vascular/mechanical component.

PT-141 also demonstrates activity at MC3R, which contributes to energy homeostasis and inflammatory regulation. The compound was derived from the linear peptide alpha-MSH analogue Melanotan II through removal of the C-terminal amide, which eliminated the tanning effects while preserving melanocortin receptor agonism relevant to sexual function.

PT-141 originated from research into Melanotan II (MT-II), an alpha-melanocyte-stimulating hormone (alpha-MSH) analogue developed at the University of Arizona in the 1990s for sunless tanning. During clinical trials of MT-II, researchers unexpectedly observed that the compound consistently produced spontaneous penile erections in male subjects — an effect not attributable to its melanogenic properties.

Palatin Technologies subsequently developed PT-141 (Bremelanotide) by modifying the MT-II structure to isolate the sexual function effects from tanning activity. Phase II and Phase III clinical trials demonstrated efficacy in both male erectile dysfunction (particularly in patients who did not respond to PDE5 inhibitors) and female hypoactive sexual desire disorder (HSDD). In 2019, the FDA approved Bremelanotide under the brand name Vyleesi for the treatment of acquired, generalised HSDD in premenopausal women — making it the first melanocortin-based therapy approved for sexual dysfunction and only the second drug ever approved for female sexual desire disorders.